MPH gets its pharmacological effect by modifying the DA system; it can block the DAT and noradrenaline (NA) transporters and then increase the extracellular DA concentrations in the prefrontal cortex and striatum of ADHD children or experimental animals [16, 17]. The gene discussed is SLC6A3; the disease is attention deficit-hyperactivity disorder.